Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.

MLA

Siemeling, O., et al. “Study Protocol of the GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A Randomized, Double-Blind, Placebo-Controlled, Single Center Trial with Ambroxol in Parkinson Patients with a GBA Mutation.” BMC Neurology, vol. 24, no. 1, May 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12883-024-03629-9.

APA

Siemeling, O., Slingerland, S., van der Zee, S., & van Laar, T. (2024). Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation. BMC Neurology, 24(1), 1–10. https://doi.org/10.1186/s12883-024-03629-9

Chicago

Siemeling, O., S. Slingerland, S. van der Zee, and T. van Laar. 2024. “Study Protocol of the GRoningen Early-PD Ambroxol Treatment (GREAT) Trial: A Randomized, Double-Blind, Placebo-Controlled, Single Center Trial with Ambroxol in Parkinson Patients with a GBA Mutation.” BMC Neurology 24 (1): 1–10. doi:10.1186/s12883-024-03629-9.